Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QGEN Stock Forecast 2025-2026
$41.85
Current Price
$9.05B
Market Cap
Buy 8
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to QGEN Price Targets
+31.4%
To High Target of $55.00
+15.1%
To Median Target of $48.17
+5.1%
To Low Target of $44.00
QGEN Price Momentum
-2.2%
1 Week Change
-0.3%
1 Month Change
-4.0%
1 Year Change
-6.0%
Year-to-Date Change
-12.7%
From 52W High of $47.93
+11.2%
From 52W Low of $37.63
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching QIAGEN (QGEN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on QGEN and similar high-potential opportunities.
Latest QGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, QGEN has a neutral consensus with a median price target of $48.17 (ranging from $44.00 to $55.00). The overall analyst rating is Buy (7.5/10). Currently trading at $41.85, the median forecast implies a 15.1% upside. This outlook is supported by 8 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 31.4% upside. Conversely, the most conservative target is provided by Timothy Daley at Wells Fargo, suggesting a 5.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QGEN Analyst Ratings
8
Buy
8
Hold
0
Sell
QGEN Price Target Range
Low
$44.00
Average
$48.17
High
$55.00
Current: $41.85
Latest QGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Baird | Catherine Schulte | Neutral | Maintains | $43.00 |
| Apr 4, 2025 | Redburn Atlantic | Ed Ridley-Day | Neutral | Downgrade | $0.00 |
| Feb 19, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $42.00 |
| Feb 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $48.00 |
| Jan 6, 2025 | Morgan Stanley | Steve Beuchaw | Equal-Weight | Downgrade | $48.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Upgrade | $54.00 |
| Oct 17, 2024 | HSBC | Shubhangi Gupta | Hold | Downgrade | $0.00 |
| Aug 2, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $52.00 |
| Jun 27, 2024 | Wolfe Research | Doug Schenkel | Outperform | Upgrade | $50.00 |
| Jun 18, 2024 | JP Morgan | Casey Woodring | Overweight | Maintains | $54.00 |
| May 1, 2024 | Stifel | Daniel Arias | Hold | Maintains | $45.00 |
| Feb 16, 2024 | Morgan Stanley | Steve Beuchaw | Overweight | Upgrade | $51.00 |
| Feb 8, 2024 | JP Morgan | Tycho Peterson | Overweight | Maintains | $52.00 |
| Feb 8, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $60.00 |
| Dec 20, 2023 | JP Morgan | Tycho Peterson | Overweight | Maintains | $50.00 |
| Dec 19, 2023 | Wells Fargo | Timothy Daley | Equal-Weight | Initiates | $44.00 |
| Dec 13, 2023 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
| Dec 7, 2023 | Goldman Sachs | Matthew Sykes | Buy | Upgrade | $0.00 |
| Nov 2, 2023 | UBS | John Sourbeer | Neutral | Maintains | $42.00 |
| Oct 17, 2023 | JP Morgan | Tycho Peterson | Overweight | Maintains | $50.00 |
Qiagen N.V. (QGEN) Competitors
The following stocks are similar to QIAGEN based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Qiagen N.V. (QGEN) Financial Data
Qiagen N.V. has a market capitalization of $9.05B with a P/E ratio of 110.2x. The company generates $2.00B in trailing twelve-month revenue with a 4.7% profit margin.
Revenue growth is +5.4% quarter-over-quarter, while maintaining an operating margin of +26.7% and return on equity of +2.7%.
Valuation Metrics
Market Cap
$9.05B
Enterprise Value
$9.51B
P/E Ratio
110.2x
PEG Ratio
18.3x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+5.4%
Gross Margin
+63.9%
Operating Margin
+26.7%
Net Margin
+4.7%
EPS Growth
+12.5%
Financial Health
Cash/Price Ratio
+10.6%
Current Ratio
3.4x
Debt/Equity
41.3x
ROE
+2.7%
ROA
+5.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Qiagen N.V. (QGEN) Business Model
About Qiagen N.V.
What They Do
Biotechnology company specializing in molecular testing technologies.
Business Model
Qiagen generates revenue by providing a wide range of sample and assay technologies for molecular testing applications. Its products are utilized across various sectors including academic research, pharmaceuticals, and clinical diagnostics, allowing the company to capture diverse market segments and maintain a steady stream of income.
Additional Information
Founded in 1984, Qiagen is a leader in genomic science and diagnostics, focusing on innovations that aid in disease detection and drug development. The company collaborates with research institutions and healthcare providers, emphasizing its commitment to advancing scientific research and improving healthcare outcomes globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,100
CEO
Mr. Thierry Bernard
Country
Netherlands
IPO Year
1996
Website
www.qiagen.comQiagen N.V. (QGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
May 07, 2025
By Zacks Equity Research
Fundamental Analysis
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
QGEN or RGEN: Which Is the Better Value Stock Right Now?
QGEN vs. RGEN: Which Stock Is the Better Value Option?
May 02, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Qiagen N.V. will hold its Q1 2025 Earnings Conference Call on May 8, 2025, at 9:00 AM ET, featuring key executives and analysts from major financial institutions.
Why It Matters
Qiagen's upcoming earnings call is a key opportunity for investors to gauge the company's financial health and strategic direction, influencing stock performance and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
QGEN reported a strong quarterly performance in Q1 2025, driven by a resilient product portfolio.
Why It Matters
QGEN's strong quarterly performance indicates stability and growth potential, suggesting a positive outlook for revenue and profitability, which could enhance investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QIAGEN N.V. plans to propose an annual cash dividend at its AGM on June 26, 2025, as part of a new dividend policy aimed at enhancing shareholder returns while allowing for reinvestment.
Why It Matters
QIAGEN's proposed annual cash dividend signals a shift toward enhancing shareholder returns, which may attract investors seeking income and indicate financial stability and growth potential.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
QIAGEN N.V. (NYSE: QGEN) reported Q1 2025 net sales of $483 million, a 5% increase from Q1 2024. The company reaffirmed its FY 2025 outlook based on strong performance and macroeconomic trends.
Why It Matters
QIAGEN's strong Q1 2025 results and reaffirmed FY outlook indicate solid performance and growth potential, signaling investor confidence and stability in the company amidst macroeconomic changes.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Qiagen (QGEN) reported Q3 earnings of $0.55 per share, exceeding the Zacks Consensus Estimate of $0.50 and up from $0.47 per share year-over-year.
Why It Matters
Qiagen's earnings beat expectations and show year-over-year growth, indicating strong performance and potential for future profitability, which can positively influence investor sentiment and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Qiagen's Q1 2025 financial results show performance metrics compared to Wall Street estimates and prior year figures, indicating potential insights for investors.
Why It Matters
Qiagen's performance against Wall Street estimates and previous year metrics can signal growth potential or weaknesses, impacting investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About QGEN Stock
What is Qiagen N.V.'s (QGEN) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Qiagen N.V. (QGEN) has a median price target of $48.17. The highest price target is $55.00 and the lowest is $44.00.
Is QGEN stock a good investment in 2025?
According to current analyst ratings, QGEN has 8 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QGEN stock?
Wall Street analysts predict QGEN stock could reach $48.17 in the next 12 months. This represents a 15.1% increase from the current price of $41.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Qiagen N.V.'s business model?
Qiagen generates revenue by providing a wide range of sample and assay technologies for molecular testing applications. Its products are utilized across various sectors including academic research, pharmaceuticals, and clinical diagnostics, allowing the company to capture diverse market segments and maintain a steady stream of income.
What is the highest forecasted price for QGEN Qiagen N.V.?
The highest price target for QGEN is $55.00 from Patrick Donnelly at Citigroup, which represents a 31.4% increase from the current price of $41.85.
What is the lowest forecasted price for QGEN Qiagen N.V.?
The lowest price target for QGEN is $44.00 from Timothy Daley at Wells Fargo, which represents a 5.1% increase from the current price of $41.85.
What is the overall QGEN consensus from analysts for Qiagen N.V.?
The overall analyst consensus for QGEN is neutral. Out of 18 Wall Street analysts, 8 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $48.17.
How accurate are QGEN stock price projections?
Stock price projections, including those for Qiagen N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:58 PM UTC